<ѻýҕl>TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progressionѻýҕl> More than a fifth of patients responded to lenvatinib-pembrolizumab combination Jul 26, 2022
<ѻýҕl>Sexual Dysfunction, Hair Loss Among Long COVID Symptomsѻýҕl> Wider range of post-COVID symptoms emerge than previously thought Jul 25, 2022
<ѻýҕl>A Monkeypox Momentѻýҕl> Let's use the lessons we learned from COVID-19 to battle this new disease threat Jul 25, 2022
<ѻýҕl>Dear Acne: You've Ruined My Life, I Hate Youѻýҕl> Personifying acne, scarring provides new insight into psychosocial burden of condition Jul 22, 2022
<ѻýҕl>Topical JAK Inhibitor OK'd for Repigmentation of Vitiligoѻýҕl> Significantly more patients achieved 75%, 90% improvement Jul 19, 2022
<ѻýҕl>Novel Nitric Oxide Gel Clears Kids' Molluscum Contagiosum Lesionsѻýҕl> Children may not need to "wait it out" for much longer, positive trial suggests Jul 13, 2022
<ѻýҕl>Make the Diagnosis: She’s Too Young for Lines on Her Faceѻýҕl> A 9-year-old girl was brought to the doctor by her mother after noticing a rash that had developed on the girl's face over the past week. Jul 13, 2022
<ѻýҕl>Chronic, Disfiguring Facial Rash With No Itching or Painѻýҕl> Female patient reports low quality of life after 10 years of treatments with no response Jul 11, 2022
<ѻýҕl>Odevixibat Scratches the Itch of Kids' Rare Liver Diseaseѻýҕl> Phase III trial showed reduced pruritus in progressive familial intrahepatic cholestasis Jul 08, 2022
<ѻýҕl>Which Biologics Stick Longest for Psoriasis?ѻýҕl> British data highlight factors affecting drug longevity Jul 06, 2022
<ѻýҕl>Does Sunlight Trigger Lupus?ѻýҕl> Analysis of data from major study suggests "yes," but falls short of clear conclusion Jun 22, 2022
<ѻýҕl>Health Equity, Gun Violence Prevention Among Priorities for AMA's New Presidentѻýҕl> Jack Resneck, Jr., MD, talks about running "the race we're in" Jun 15, 2022
<ѻýҕl>FDA Approves First Systemic Treatment for Alopecia Areataѻýҕl> Four to 10 times as many patients met hair-regrowth endpoint with JAK inhibitor versus placebo Jun 13, 2022
<ѻýҕl>Something Fishy About Tuna and Melanoma Riskѻýҕl> Higher total fish intake linked with 22% higher risk of malignant tumors Jun 09, 2022
<ѻýҕl>Novel IL-17 Inhibitor Passes Mid-Stage Test in Psoriatic Arthritisѻýҕl> Phase II results suggest drug could outperform existing agents Jun 03, 2022
<ѻýҕl>Why the Atypical Symptoms in the Latest Monkeypox Cases?ѻýҕl> Experts agree these cases are unusual, but not necessarily a concern for viral mutation May 27, 2022
<ѻýҕl>Lance Bass' Psoriatic Arthritisѻýҕl> "I just figured it was because of dancing," says former member of 'NSYNC May 26, 2022
<ѻýҕl>FDA OKs First Novel Nonsteroidal Topical for Plaque Psoriasis in 25 Yearsѻýҕl> Complete, near-complete clearance in 35-40% of patients treated with tapinarof cream 1% May 24, 2022
<ѻýҕl>Oral Retinoid May Ease Painful Skin Reactions to Anticancer Therapyѻýҕl> Preliminary data on acitretin therapy are promising May 11, 2022
<ѻýҕl>In Lupus, 'Normal-Appearing' Skin Is Not Normalѻýҕl> Groundwork for inflammation laid before lesions develop Apr 27, 2022
<ѻýҕl>Testing for Th/To Antibodies May Help in Scleroderma Managementѻýҕl> Test identifies patients at high risk for pulmonary hypertension Apr 25, 2022
<ѻýҕl>FDA OKs New Topical for Inflammatory Rosaceaѻýҕl> Almost half of patients clear of lesions or nearly so with benzoyl peroxide 5% cream (Epsolay) Apr 25, 2022
<ѻýҕl>Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1ѻýҕl> But response rate driven primarily by injected lesions, expert points out Apr 14, 2022
<ѻýҕl>Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1ѻýҕl> Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone Apr 13, 2022
<ѻýҕl>Response in Kids With Psoriasis Maintained Long Term With IL-17A Inhibitorѻýҕl> At least 75% improvement at 108 weeks in patients treated with ixekizumab Apr 13, 2022
<ѻýҕl>Smoker's Painless Skin Nodules Flag a Fatal Diagnosisѻýҕl> Skin metastasis was the first sign for the otherwise asymptomatic patient Apr 04, 2022
<ѻýҕl>First Topical Therapy for Facial Angiofibroma Nabs FDA Approvalѻýҕl> New alternative to dermabrasion, laser treatment, surgery Apr 04, 2022
<ѻýҕl>Chronic Spontaneous Urticaria Responds Quickly to BTK Inhibitorѻýҕl> AAD data also promising for therapies in psoriasis, pyoderma gangrenosum Mar 31, 2022
<ѻýҕl>Psoriasis Therapy Has Mixed Effects on Cardiovascular Risk Factorsѻýҕl> No reduction in vascular inflammation with apremilast but significant reduction in body fat Mar 30, 2022
<ѻýҕl>Meta-Analysis of Atopic Dermatitis Drugs Favors Two JAK Inhibitorsѻýҕl> Small advantages for abrocitinib, upadacitinib, but data still accumulating for all the players Mar 30, 2022
<ѻýҕl>Toward More Uniform Methotrexate Dosing in Psoriasisѻýҕl> International expert group urges common standards Mar 30, 2022
<ѻýҕl>Jada Pinkett Smith's Alopeciaѻýҕl> The condition at the center of this year's Academy Awards drama Mar 29, 2022
<ѻýҕl>Significant Improvement in Vitiligo With JAK Inhibitor Therapyѻýҕl> Durable improvement in pigmentation with topical ruxolitinib, oral ritlecitinib Mar 29, 2022
<ѻýҕl>Atopic Dermatitis: Promising Data for New Mechanistic Approachѻýҕl> Rapid responses in a majority of patients in small trial of eblasakimab Mar 28, 2022
<ѻýҕl>Targeted Antibody Provides Significant Relief From Itchy Nodular Conditionѻýҕl> Dupilumab reduces itch, lesion count in first phase III trial for prurigo nodularis Mar 28, 2022
<ѻýҕl>Dramatic, Durable Hair Growth With Oral JAK Inhibitorѻýҕl> Oral baricitinib superior to placebo at 36 weeks in BRAVE-AA1 and BRAVE-AA2 trials Mar 27, 2022
<ѻýҕl>Novel Fixed-Dose Immunotherapy Combo Wins FDA Approvalѻýҕl> Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
<ѻýҕl>Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancerѻýҕl> Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
<ѻýҕl>Clinic-Based Hidradenitis Suppurativa Surgery Gets High Marks From Patientsѻýҕl> High satisfaction after three-fourths of procedures, despite frequent recurrences Mar 17, 2022
<ѻýҕl>Extension Study Confirms JAK Inhibitor's Activity in Atopic Dermatitisѻýҕl> EASI75 response rate exceeding 80% through 52 weeks of upadacitinib treatment Mar 16, 2022